AzTrials
AzTrials

Atrial FibrillationSAFFICIENTNCT06488820

Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers (SAFFICIENT)

An observational study of Atrial Fibrillation, run by Texas Cardiac Arrhythmia Research Foundation at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Catheter ablation using radiofrequency (RF) energy has been widely adopted for management of atrial fibrillation (AF) for the past several years. However, heterogeneity of outcomes and complication rates are still reported that have been partly attributed to operator's experience and center's procedure volume (1). Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Atrial Fibrillation
What is being tested?
Catheter ablation using pulsed-field ablation (PFA) system
Type of treatment
Medical device
How many people
75 participants
Where
1 siteUnited States
Study dates
29 Aug 2024to 4 Apr 2025
How long will I take part?
11 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with atrial fibrillation

Who may be able to join

  • Age: >≥18 years
  • Symptomatic Paroxysmal or Persistent AF patients of ≤ 1 year
  • First ablation or redo procedure to treat AF
  • Willing to provide written informed consent
  • Able and willing to comply with all testing and requirements

Who cannot join

  • Long-standing persistent AF Page 17 of 70
  • Any condition contraindicating chronic anticoagulation
  • Prosthetic mechanical valves
  • Recent MI (in <3 months)
  • Active systemic infection
  • Pregnant or lactating women
Show all 11Show fewer
  • Current enrollment in an investigational study evaluating another device or drug.
  • Documented left atrial (LA) thrombus by imaging within 48 hours before procedure (computed tomography (CT), transesophageal echocardiogram (TEE), or intracardiac echocardiogram (ICE) at the beginning of the procedure).
  • Uncontrolled heart failure or New York Heart Association (NYHA) Class IV
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
  • Life expectancy less than 12 months

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Texas Cardiac Arrhythmia

    Austin, Texas, 78705

Other trials in United States

About this study

Official title: Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers

Catheter ablation using radiofrequency (RF) energy has been widely adopted for management of atrial fibrillation (AF) for the past several years.

However, heterogeneity of outcomes and complication rates are still reported that have been partly attributed to operator's experience and center's procedure volume (1). In a meta-analysis of 14 studies, both hospital volume of ≥50 and ≥100 procedures per year were associated with significantly lower complication rate compared to <50/year (2).

Read more

Pulse-field ablation (PFA) is an emerging technology for AF management that has demonstrated tremendous potential in terms of preferential tissue ablation with no damage to the adjacent organs. In the MANIFEST-PF survey, 24 European centers participated that had a mean of 704 ablations per year with 73.3 (range 7-291) PFA ablations annually (3). No post-PFA esophageal complications, PV stenosis or persistent phrenic nerve injury were reported. There appeared to be a trend toward fewer complications with center experience, particularly for pericardial tamponade (3).

However, the impact of number of PFA performed on procedure-success and safety has not been evaluated in the US.

This multicenter prospective study is designed to compare the incidence of adverse event (AE) and long-term procedural success of pulse-field ablation for AF in low volume (<100/year) vs. high volume (≥100/year) centers.

Read the detailed description

Prospective, non-randomized, multi-center study NUMBER OF STUDY CENTERS: Up to 80 TRIAL OBJECTIVE To evaluate safety of the VARIPULSE™ Catheter when used in conjunction with the TRUPULSE™ Generator for catheter ablation in low volume centers, compared to high-volume centers, for the treatment of subjects with symptomatic atrial fibrillation, excluding long-standing persistent AF.

HYPOTHESIS The low volume centers would be noninferior to high volume centers with respect to the proportion of patients experiencing at least one primary adverse event (PAE).

ABLATION PROCEDURE All left atrial ablations such as pulmonary vein isolation (PVI) and isolation of left atrial posterior wall will be performed using the PFA system. If the right atrial structures are needed to be ablated (i.e. cavotricuspid isthmus line, coronary sinus), a commercially approved radiofrequency (RF) catheter and compatible RF generator will be used.

MANDATORY: Minimum applications per vein is 12, Maximum applications per vein is 20 Ablation Outside the PV

Ablation outside the PVs will be performed only in the presence of spontaneous triggers or documentation that those locations are the sites for triggers responsible for re-initiation of the arrhythmia either spontaneously or after isoproterenol challenge. For ablation outside the pulmonary vein, the number of applications will be determined on a case- by-case basis based on the expected tissue thickness in the ablation area. At a minimum, at least 6 applications per area (3 applications at 2 catheter rotations) should be considered. Each lesion set attempted will be assessed for acute efficacy (bi-directional block, absence of detectable electrograms). Additional lesions should be given until the acute endpoint is met.

Posterior wall ablations: Concentric overlapping ablations should be placed onto the posterior wall deliberately. The catheter will be rotated once between a pair of applications; briefly, rotation is performed such that, post-rotation, the splines are situated midway between the splines' pre- rotation positions. The number of applications will be at the operator's discretion.

DURATION OF SUBJECT PARTICIPATION:

11 months after the index ablation procedure (2 months blanking + 9 months follow-up)

DURATION OF STUDY 2-3 years (1-2 year of enrollment+ 11 months of study duration)

STATISTICS

The sample size and power calculation were performed to establish noninferiority (NI) of low volume centers with respect to the primary safety endpoint. With a NI margin of 0.04, an estimated sample size of 1084 patients per group will provide 80% power at one-sided significance level of 2.5% to declare non-inferiority. Considering 5% oversampling for attrition, 1138 patients will be enrolled per group.

Interim analysis: None planned

Being tested
Catheter ablation using pulsed-field ablation (PFA) system
Keywords
pulsed-field ablation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Catheter ablation using pulsed-field ablation (PFA) systemDevice

    PFA will be used to isolate the pulmonary veins and additional left atrial structure as needed

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety of PFA

    Adverse events

    Measured: 1 year

Secondary outcomes (1)
  1. Efficacy of PFA

    Arrhythmia-free on- or off-antiarrhythmic drugs

    Measured: 2-mo blanking period+ 11 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jul 2024
  2. Study start29 Aug 2024
  3. Primary completion4 Apr 2025
  4. Study completion4 Apr 2025

Why it stopped: Given the recent FDA approval of the VARIPULSE platform in November 2024, J\&J MedTech and the PI have made the strategic decision to phase out SAFFICIENT IDE to focus on the post-approval study

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
75 participants (actual)
Target duration
11 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06488820
Sponsor's protocol ID
TCAI_SAFFICIENT
Acronym
SAFFICIENT
Status last verified
May 2025
First submitted
24 Jun 2024
Last updated
28 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation, run by Texas Cardiac Arrhythmia Research Foundation at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 28 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Given the recent FDA approval of the VARIPULSE platform in November 2024, J\&J MedTech and the PI have made the strategic decision to phase out SAFFICIENT IDE to focus on the post-approval study). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety of PFA (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2025; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in